http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106474106-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0d44338a9983e0302c286cb9d319ff9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 |
| filingDate | 2016-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_685253980351b754f8ecf6867157fabf |
| publicationDate | 2017-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106474106-A |
| titleOfInvention | Application of the linderolide H in preventing and treating hepar damnification medicine is prepared |
| abstract | The present inventor discloses linderolide H has protective action, the acute liver to CCl4 induction to have protective action to the acute liver that D amine-galactose amine (D galactosamine, D GalN) is induced.Therefore, linderolide H can be used for the medicine for preparing preventing and treating hepatic injury or hepatitis, first public, as framework types belong to brand-new framework types, and which is strong for the therapeutic action activity of hepar damnification, possess prominent substantive distinguishing features, be simultaneously used for anti-hepar damnification and obviously there is significant progress. |
| priorityDate | 2016-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.